Business Wire

AZ-SUPIMA/TEXTILEGENESIS

13.6.2022 10:02:09 CEST | Business Wire | Press release

Share
Supima Partners With TextileGenesis to Set New Industry Benchmark on Traceability

Supima, the brand for American-grown Pima cotton, announces a strategic partnership with TextileGenesis™ to establish the new industry benchmark platform for authenticating cotton.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005099/en/

The Supima blockchain platform powered by TextileGenesis™ will digitally connect Supima’s comprehensive supply chain from the growers to the brand/retailers. Integrated with this digital platform, Supima’s technology partner Oritain™ will provide the forensic origin authentication for Supima cotton across the platform. The ability to independently validate the Supima content of products at every stage of the supply chain achieves unmatched authenticity and responsibility through the combination of forensic physical and digital authentication.

Since it was founded in 1954, SUPIMA® has been referred to as the “world’s finest cottons.” Today marks the next chapter in Supima’s ongoing leadership role in bringing the most trusted and robust verification solution to authentic premium fiber sourcing to the global fashion industry. SUPIMA® is fortunate to partner with brands and retailers that are leaders in transparency and responsible sourcing. This ground-breaking supply chain traceability platform will provide an underlying mechanism to collaborate with the partners in a transparent, and verifiable way.

TextileGenesis’ Fibercoin™ technology will be integrated into Supima’s licensing program and applied to all SUPIMA® branded fiber throughout the supply chain, creating a non-fungible digital token for every kilogram of Supima cotton that can be physically and forensically verified and authenticated by Supima from the farm through to the retail shelf. This pioneering effort for cotton sourcing sets a new standard for responsibility in the global textile industry and consumer marketplace. Supima is striving to bring deeper levels of authenticity and responsibility to cotton sourcing with greater support for equity and ubiquity for all partners in the supply chain.

“The Supima partnership with TextileGenesis provides for the very first time, undisputable proof of origin for consumer products all the way back to the fiber’s origin. This enables Supima’s partner brands to credibly claim advantages in terms of product quality and sustainability that are independently verifiable through both digital and forensic testing. There is no system like this for any other fiber. SUPIMA® partners will have the most authentic and trustworthy premium cotton source for all the current and future needs of luxury apparel and home textile products,” says Marc Lewkowitz, President and CEO of Supima.

“This collaboration is setting a new benchmark for the cotton and premium fiber’s industry, and paves a new path for the entire fashion eco-system. We are creatively combining three major innovations - digital-tokens based article-level traceability, forensic physical verification, and Supima brand-licensing - in a single integrated platform. It creates a new platinum standard in the industry for end-to-end traceability and physical verification,” says Amit Gautam, Founder and CEO of TextileGenesis.

ABOUT TEXTILEGENESIS
TextileGenesis is a market-leading traceability platform custom-built for the fashion and textile ecosystem. It has partnered with 40+ leading global brands to create fiber-to-retail traceability for sustainable, premium and certified materials. By the end of 2022, TextileGenesis will create traceability for 500 million+ units in the global fashion industry.

ABOUT SUPIMA
Supima is America’s luxury cotton: founded in 1954, the Supima brand, short for “Superior Pima,” designates an exclusive source of exceptional extra-long staple cotton responsibly grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color, indulgent softness, and durability.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye